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OXA-163-Producing Klebsiella pneumoniae in Cairo, Egypt, in 2009
and 2010
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Two genetically unrelated OXA-163-carrying Klebsiella pneumoniae strains were identified from two infection cases in June
2009 andMay 2010 in Cairo, Egypt. OXA-163-producing Enterobacteriaceae had been previously reported in Argentina only.
Both patients had no history of travel abroad. The emergence of this newly recognized OXA-48-related -lactamase able to hy-
drolyze cephalosporins and carbapenems is especially worrying in a geographic area where OXA-48 is endemic and effective sur-
veillance for antibiotic resistance is largely unaffordable.
Carbapenems are first-line drugs for severe infections caused byextended-spectrum -lactamase (ESBL)-producing Entero-
bacteriaceae. However, the emergence and rapid diffusion of car-
bapenemase-producing Gram negatives in the recent years is
compromising the therapeutic efficacy of this class of antimicro-
bial drugs (2, 11, 16).
Recently, two blaOXA-163-producing isolates of Klebsiella pneu-
moniae and Enterobacter cloacae have been identified in Argentina
(15). OXA-163 differs from OXA-48 by a single amino acid sub-
stitution and a 4-amino-acid deletion only, but it works as an
extended-spectrum oxacillinase showing a weaker ability to hy-
drolyze carbapenems than OXA-48 but a concurrent significant
ability to hydrolyze extended-spectrum cephalosporins (15). The
blaOXA-163 gene has been putatively proposed as the equivalent in
South America of the blaOXA-48 gene that is increasingly identified
in the southern and eastern Mediterranean countries (1, 6, 8, 14).
Here, we report two autochthonous cases of infection caused
by two genetically unrelated OXA-163-carrying K. pneumoniae
strains in Cairo, Egypt, in 2009 and 2010.
Case 1 was a 31-year-old woman hospitalized in Cairo (Egypt)
on June 5, 2009, due to acute myelocytic leukemia. She was on
therapy by doxorubicin and cytarabine. After 16 days since admis-
sion, she was transferred to an intensive care unit because of heart
and respiratory failure. Initial antibiotic therapy was started with
vancomycin, azithromycin, and imipenem. Blood culture was
positive for a carbapenem-resistant strain of K. pneumoniae (iso-
late 18). The patient died on June 23.
Case 2 was a 25-year-old man with an 18-month history of
acute lymphocytic leukemia. He was in outpatient follow-up until
May 2010, when he was admitted to the hospital due to a lower
respiratory tract infection. He was started on cefepime and ami-
kacin on May 14, but the clinical course was complicated. A spu-
tum culture grew carbapenem-resistant K. pneumoniae (isolate
78). No further data about the treatment outcome were available
for this patient.
Both patients had never traveled outside Egypt.
The two carbapenem-resistantK. pneumoniae strainswere sent
to the molecular epidemiology laboratory of the Department of
Sciences for Health Promotion “G. D’Alessandro,” University of
Palermo, Italy, for confirmation and typing. The two isolates were
initially tested for antimicrobial susceptibility by disk diffusion
according to the Clinical and Laboratory Standards Institute
(CLSI) guidelines (3). Susceptibility testing for extended-spec-
trum cephalosporins and carbapenems was performed with Etest
strips (bioMérieux, Marnes-La-Coquette, France). Results were
interpreted according to the CLSI interpretative criteria (3).
PCR screening for carbapenemase-encoding genes of classes A
(blaKPC, blaGES), B (blaVIM, blaIMP), and D (blaOXA-48) and for
ESBL-encoding genes blaTEM, blaOXA, blaSHV, and blaCTX-M was
performed as described previously (4). PCR products were puri-
fied and sequenced using the BigDye Terminator version 1.1 cycle
sequencing kit (Applied Biosystems, Warrington, United King-
dom) and the ABI Prism 310 Genetic Analyzer (Applied Biosys-
tems, Foster City, CA). The nucleotide (nt) and deduced protein
sequences were analyzed with the software available from the Na-
tional Center for Biotechnology Information website (www.ncbi
.nlm.nih.gov). Outer membrane protein (OMP) gene amplifica-
tion was conducted using ompK35-F and -R and ompK36-F and
-R, and PCR products were sequenced using OMP primers ac-
cording to Kaczmarek et al. (8). The sequences were analyzed by
comparison with reported nucleotide sequences in GenBank. Ex-
pression levels of the ompK35 and ompK36 genes were not inves-
tigated.
To evaluate their clonal relationship, the two K. pneumoniae iso-
lates were submitted to pulsed-field gel electrophoresis (PFGE) after
XbaIDNAdigestion. StraindifferentiationbyPFGEwasbasedon the
criteria of Tenover et al. (17). The rep-PCR DiversiLab Microbial
Typing System (bioMérieux, Marcy l’Étoile, France) was also used
with the DiversiLabKlebsiella kit. DNA fragment separation and de-
tection were done using the Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, SantaClara, CA), and resultswere analyzed and interpreted
using the Kullback-Leibler method, as previously reported (13).
Moreover, multilocus sequence typing (MLST) was performed on
both isolates according to the protocol described on the K. pneu-
moniae MLST website (http://www.pasteur.fr/recherche/genopole
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/PF8/mlst/Kpneumoniae.html). MLST results were compared with
the internationalK. pneumoniaeMLST database at the Pasteur Insti-
tute in Paris, France.
The twoK. pneumoniae isolates exhibited resistance to extended-
spectrum cephalosporins (cefotaxime, ceftazidime, cefepime),
aztreonam, and carbapenems (meropenem and imipenem) (Ta-
ble 1). Additionally, both isolates were resistant to ciprofloxacin
and gentamicin and susceptible to colistin.
For both isolates, positive PCR results were obtained for the
blaTEM, blaSHV, and blaCTX-M genes, and sequencing identified
the narrow-spectrum -lactamase TEM-1 and SHV-1 genes and
the ESBL CTX-M-15. A blaOXA-48-like gene was detected by PCR
in both isolates that, by sequencing, was identified as blaOXA-163
(www.lahey.org).
The ompK35 and ompK36 genes of isolates 18 and 78 were
amplified, sequenced, and aligned with those of OMP gene se-
quences ofK. pneumoniaeMGH78578. The ompK35 gene of both
isolates showed a frameshiftmutation due to a nucleotide deletion
at nt 873. Moreover, in the ompK35 gene of isolate 18, sequencing
revealed one substitution, T¡A, at nucleotide position 108, gen-
erating a TAA nonsense mutation which resulted in a premature
stop codon at amino acid position 36. Silent pointmutations were
also found at nt 303, 420, 537, 648, and 786 on the nucleotide
sequence of both isolates. Comparison of the ompK36 gene se-
quence with the wild-type sequence revealed that both had an
insertion of six nucleotides (5=-GGCGAC-3=) at positions 405 to
410, due to a duplication of the adjacent region at nucleotide po-
sitions 399 to 404. Sequencing of the ompK36 sequence of isolate
78 detected also a 9-nucleotide deletion at positions 556 to 564.
PFGE and rep-PCR showed that the two isolates were geneti-
cally unrelated to each other (Fig. 1). Additionally, MLST attrib-
uted two different sequence types, ST37 and ST20, respectively, to
the strains 18 and 78.
The main characteristics of the two isolates of K. pneumoniae
are summarized in Table 1.
The findings of this study are of concern for a number of rea-
sons. First, the detection of OXA-163 outside the continent where
it has been firstly identified was unexpected. This finding seems to
stand against the hypothesis of OXA-163 as the equivalent in
South America of OXA-48 in the Mediterranean area (15). The
two patients had no history of travel abroad. Moreover, possible
contacts with source patients from Argentina, though it was not
possible to investigate them in detail, appear to be unlikely due
also to the 1-year-long interval of time between the two cases. An
autochthonous emergence in Egypt of the OXA-163 resistance
determinant appears to be the more plausible explanation. Sec-
ond, the two K. pneumoniae isolates were genetically unrelated
based upon PFGE andMLST. This rules out the clonal expansion
of an OXA-163-producing strain in Egypt and, alternatively, sup-
ports the hypothesis of horizontal transmission of this genetic
determinant via plasmids, according with the previous report
(14). Notably, strains belonging to ST20 and ST37 have been pre-
viously identified in different countries as ESBL or carbapenemase
producers (11, 12). Moreover, it is of special interest that OXA-
163 has been identified in Egypt, a country of North Africa, a
geographical area where OXA-48-producing Gram negatives are
considered endemic (6, 9, 10). Third, both strains had much
higher MICs for carbapenems than those reported by Poirel et al.
(15). Studies suggest that outer membrane permeability defects
coupled with ESBL production can confer resistance to carbapen-
ems (5, 7, 9). This is likely to account for the higher level of car-
bapenem resistance detected in our strains. It is also noteworthy
that the presence of similar mutations altering the properties of
the OmpK35 andOmpK36 porins have been previously described
in an ST37 K. pneumoniae clone carrying blaCTX-M-15 and exhib-
iting reduced susceptibility to carbapenems (5). However, our
study did not definitively attribute the carbapenem resistance
phenotype to OXA-163, because transfer of antimicrobial agent
resistance experiments and plasmid analysis were not performed.
This is a substantial limitation of our report.
As previously reported about OXA-163-producing strains in
Argentina, because of its unique hydrolysis ability mimicking a
class A ESBL, OXA-163 could be able to spread unrecognized as a
TABLE 1Main characteristics of two OXA-163-producing K. pneumoniae isolates detected in Egypt, June 2009 and May 2010
K. pneumoniae
strain
(patient)
MIC (g/ml)a
bla genes
Sequence
typeCefotaxime Ceftriaxone Ceftazidime Aztreonam Imipenem Meropenem Colistin
18 (case 1) 256 256 256 256 6 8 0.25 TEM-1, SHV-1, CTX-M15,
OXA-163
37
78 (case 2) 256 256 256 256 6 12 0.25 TEM-1, SHV-1, CTX-M15,
OXA-163
20
a MICs assessed by Etest.
FIG 1 XbaI pulsed-field gel electrophoresis patterns and rep-PCR patterns of
two OXA-163-carrying Klebsiella pneumoniae strains, Cairo, Egypt, 2009 and
2010. (A) Lanes: MW, XbaI-digested DNA of Salmonella Braenderup H9812;
1, K. pneumoniae strain 18; 2, K. pneumoniae strain 78. (B) Lanes: 1, K. pneu-
moniae strain 18; 2, K. pneumoniae strain 78.
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carbapenemase (15). Surveillance of emergence and dissemina-
tion of enterobacteria with complex carbapenem resistancemech-
anisms is a serious public health problem where the costs can be
unaffordable, such as low-resource countries. Further studies are
urgently needed to assess prevalence of the blaOXA-163 genetic de-
terminant worldwide.
Nucleotide sequence accession numbers. The ompK35 of iso-
late 78was assigned accession number JQ660370, and the ompK36
sequences of isolates 18 and 78 were assigned accession numbers
JQ660371 and JQ660372, respectively, in the GenBank database.
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